UNSPSC 51162744: Tetrahydrozoline or tetryzoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9U025Y077, chemically known as 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1h-imidazole but more generally known as tetrahydrozoline, which bears US NIH Compound Identifier 5419. European Medicines Agency schedules Tetryzoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10955MIG.

UNSPSC 51162744 Tetrahydrozoline or tetryzoline is a Commodity code covering pharmaceutical products typically used in decongestant and ophthalmic preparations. Recent state and local opportunities show limited direct procurement of this specific ingredient; instead, purchasing bodies are buying finished pharmaceutical products and OTC preparations that may incorporate such active ingredients as part of broader health and safety initiatives. State and local issuing bodies soliciting under this code include county health departments and multistate cooperative purchasing alliances that aggregate demand across state and local facilities. The work involves establishing supply agreements for pharmaceutical products with detailed specification requirements, including National Drug Codes, packaging configurations, and compliance with cGMP and FDA regulations.

Geographic activity centers on Florida and Minnesota, based on recent postings. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026. The MMCAP procurement requires vendors to supply through three authorized wholesalers and comply with cGMP, DSCSA, and FDA requirements, with a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation.